20 related articles for article (PubMed ID: 2878008)
1. Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.
Fougère B; Vellas B; van Kan GA; Cesari M
Transl Neurosci; 2015; 6(1):103-110. PubMed ID: 28123793
[TBL] [Abstract][Full Text] [Related]
2. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.
Bhasin S; He EJ; Kawakubo M; Schroeder ET; Yarasheski K; Opiteck GJ; Reicin A; Chen F; Lam R; Tsou JA; Castaneda-Sceppa C; Binder EF; Azen SP; Sattler FR
J Clin Endocrinol Metab; 2009 Nov; 94(11):4224-33. PubMed ID: 19837911
[TBL] [Abstract][Full Text] [Related]
3. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
4. Current status and future opportunities for controlling acromegaly.
Melmed S; Vance ML; Barkan AL; Bengtsson BA; Kleinberg D; Klibanski A; Trainer PJ
Pituitary; 2002; 5(3):185-96. PubMed ID: 12812311
[TBL] [Abstract][Full Text] [Related]
5. Gingival enlargement in acromegaly.
Capoglu I; Yilmaz AB; Unüvar N; Orbak R; Aksoy H; Yesilyurt H
Endocrine; 2002 Aug; 18(3):207-10. PubMed ID: 12450310
[TBL] [Abstract][Full Text] [Related]
6. Acromegaly. Recognition and treatment.
Jaffe CA; Barkan AL
Drugs; 1994 Mar; 47(3):425-45. PubMed ID: 7514973
[TBL] [Abstract][Full Text] [Related]
7. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
9. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
Barkan AL; Beitins IZ; Kelch RP
J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
[TBL] [Abstract][Full Text] [Related]
10. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary study on the relation between serum growth hormone and 1,25-dihydroxyvitamin D3 in acromegalic patients].
Zhou X
Zhonghua Yi Xue Za Zhi; 1992 Jan; 72(1):21-3, 63. PubMed ID: 1315610
[TBL] [Abstract][Full Text] [Related]
12. Serum type III procollagen propeptide levels in acromegalic patients.
Verde GG; Santi I; Chiodini P; Cozzi R; Dallabonzana D; Oppizzi G; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1406-10. PubMed ID: 2878008
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
